Methotrexate prodrug - ROS Therapeutics
Latest Information Update: 28 May 2022
At a glance
- Originator Technical university of denmark
- Developer ROS Therapeutics
- Class Abortifacients; Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Eye disorder therapies; Glutamates; Heart failure therapies; Pterins; Small molecules
- Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Denmark